OSE Immunotherapeutics (STU:6OP) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6OP OSE Immunotherapeutics SA STU:6OP
48 GF Score
Price €3.14
GF Value €1.44
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:6OP
48GF Score
OSE Immunotherapeutics SA STU:6OP
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is OSE Immunotherapeutics (STU:6OP) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of €3.14 is trading 117.8% above its estimated GF Value™ of €1.44. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for STU:6OP:

  • Dividends Received:
  • GF Value™: €1.44 vs. price of €3.14 (117.8% above fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the STU:6OP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OSE Immunotherapeutics Business Description

Other Exchanges ORPOF:USA0RAD:UKOSE:France
Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
48GF Score

Get the complete analysis for STU:6OP

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.14
Price
€1.44
GF Value